Researchers have reported success with a new protective vaccine that
shows considerable potential against deadly leptospirosis bacteria. The
disease can cause considerable lung damage.
New research of interest has been
published in the journal
eLife ("A live attenuated-vaccine model confers cross-protective immunity against different species of the
Leptospira genus").
This is based on a study that discusses how a single-dose universal
vaccine could protect against the many forms of leptospirosis bacteria,
which
cause life-threatening conditions such as Weil’s disease and lung haemorrhage.
Leptospira bacteria refers to genus of spirochaete bacteria,
including a small number of pathogenic and saprophytic species. The
bacteria are flexulous, in terms of being able to bend and wriggle as
well as motile, in terms of being able to propel themselves about. It is
of medical concern that the disease caused by the bacterium is manifest
as a wide range of symptoms, some of which may be mistaken for other
diseases.
The time between exposure to the bacteria which causes
leptospirosis and when symptoms first become apparent is 7 to 21 days.
Posted by Dr. Tim Sandle,
Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
No comments:
Post a Comment
Pharmaceutical Microbiology Resources